Moderna (MRNA)
(Delayed Data from NSDQ)
$116.07 USD
-0.38 (-0.33%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $115.91 -0.16 (-0.14%) 7:18 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRNA 116.07 -0.38(-0.33%)
Will MRNA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNA
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
Play Likely Earnings Beat With 5 Top-Ranked Stocks
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Other News for MRNA
Tesla, Archer Aviation rise; Eli Lilly falls, Tuesday, 7/2/2024
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine
US will pay vaccine maker Moderna $176 million to develop an mRNA-based pandemic flu vaccine
IN BRIEF: Moderna gets EMA marketing nod for mResvia vaccine
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet